The Cancer Letter

Inside information on cancer research and drug development

Conversation with The Cancer Letter

Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

As artificial intelligence becomes an indispensable tool in cancer research, drug sponsors and researchers should focus on building and utilizing rich real-world evidence databases that can be used to complement clinical trials.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Paul Goldberg
Editor & Publisher
Matthew Bin Han Ong
Senior Editor
Table of Contents

YOU MAY BE INTERESTED IN

Byline
Paul Goldberg
Editor & Publisher
Matthew Bin Han Ong
Senior Editor
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account